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The diuretic bumetanide failed to treat acute seizures due to hypoxic ischemic
encephalopathy (HIE) in newborn babies and was associated with hearing loss (NEMO
trial, Pressler et al., 2015). On the other hand, clinical and experimental observations
suggest that the diuretic might provide novel therapy for many brain disorders including
Autism Spectrum Disorders (ASD), schizophrenia, Rett syndrome, and Parkinson
disease. Here, we discuss the differences between the pathophysiology of severe
recurrent seizures in the neonates and neurological and psychiatric disorders stressing
the uniqueness of severe seizures in newborn in comparison to other disorders.
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Whereas in adult (mature) neurons GABA provides most of the inhibitory tone, in immature
neurons it depolarizes and often excites due to higher levels of intracellular chloride ((Cl−)I)
(Ben-Ari et al., 1989, 2007; Ben-Ari, 2014). Extensive investigations suggest that the two chloride
co-transporters NKCC1 and KCC2 play a central role in this developmental sequence. NKCC1 and
KCC2 are respectively important chloride importers and exporters and the activity of the former
early on is thought to underlie the depolarizing and often excitatory actions of GABA on immature
neurons (reviewed in Ben-Ari, 2014). High (Cl−)I levels, depolarizing and excitatory actions of
GABA are also observed after a wide range of insults and disorders including seizures, Autism
Spectrum Disorders (ASD), chronic pain, spinal chord lesions, Down’s syndrome, brain trauma,
cerebral edema formation, cerebral artery occlusion, and diabetic ketoacidosis (Ben-Ari et al., 2007;
Boulenguez et al., 2010; Pizzarelli and Cherubini, 2011; Ben-Ari, 2014; Deidda et al., 2014; Kaila
et al., 2014). Therefore, drugs that restore low (Cl−)I levels may provide novel therapies for a wide
range of disorders. The diuretic bumetanide is one such drug that specifically blocks the NKCC1
chloride importer thereby reducing (Cl−)I levels and restoring GABAergic inhibition in many
neuronal types in physiological and pathological conditions. The recent failure of the NEMO trial
aimed at treating seizures in newborn babies with bumetanide (Pressler et al., 2015) has casted some
doubts on the therapeutic promises of bumetanide and magnified its side effects. Here, we would
like to discuss why this view is not tenable; namely the major differences between the pathogenesis
of acute neonatal seizures due to HIE and other disorders, in addition to the good tolerability of
bumetanide reported over the last four decades.
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NEMO (Pressler et al., 2015) was a phase I/II trial to assess
the safety and optimal dose of bumetanide for the treatment
of acute neonatal seizures not responding to a loading dose of
phenobarbital. Newborn babies were treated with the diuretic
in adjunct to a second dose of phenobarbital. Bumetanide did
not reach the primary endpoint (≥80% reduction in EEG seizure
burden without the need for rescue antiepileptic drugs in >50%
of the patients). The trial was terminated prematurely because
of hearing loss observed in 3 out of 11 surviving babies. The
hearing loss can be ascribed to synergetic effects of several factors
such as immaturity of hair cells, differences between the roles
of NKCC1 and KCC2 in the regulation of (Cl−)I in immature
and adult cochlear hair cells, and effects of hypoxic injury and
toxicity of aminoglycosides that are aggravated by bumetanide
(Brummett, 1981; Lu et al., 1999; Zhang et al., 2007; Abbas and
Whitfield, 2009; Milenkovic´ and Rübsamen, 2011; Wong et al.,
2013; Witte et al., 2014). Pressler and colleagues discuss these
issues at length stressing the difficulties of evaluating the potential
risks/benefit ratio in babies in severe life threatening conditions.
Bumetanide has been used including in preterm babies and
young children without ototoxicity previously (Flamenbaum and
Friedman, 1982; Laughon et al., 2015). Bumetanide is a well-
tolerated diuretic used to treat hypertension and cerebral edema
at all ages; its adverse effects are almost entirely restricted to
its diuretic effect such as hypotension and hypokalemia (Asbury
et al., 1972; Narins and Chusid, 1986) which are usually easy
to correct. Therefore, the ototoxic effect seen in the NEMO
study is specific to this age group with the additional risk factors
mentioned above.
Furthermore, the poor antiepileptic efficacy in the NEMO
trial cannot necessarily be extrapolated to other types of seizures.
Bumetanide blocks seizures in some animal models but not
others (Ben-Ari et al., 2007; Kilb et al., 2007; Nardou et al.,
2009; Ben-Ari, 2014) suggesting that the efficacy of bumetanide
is seizure type dependent. In addition, GABA exerts excitatory
actions in some models of migration disorders but not in others
(Isaev et al., 2005; Tyzio et al., 2009; Pressler et al., 2015). For
instance, in human resected slices after surgical interventions,
bumetanide reduced hyperactivity in temporal lobe epilepsy
(Cohen et al., 2006; Pallud et al., 2014) but not in Sturge-Weber
Syndrome where GABA inhibits neuronal activity (Tyzio et al.,
2009). In a case report, bumetanide reduced seizure burden in
adult temporal lobe epilepsies (Eftekhari et al., 2013; Pressler
et al., 2015). For clinical trials in neonatal seizures like NEMO,
the regulatory authorities and ethic committees request that the
administration of a new drug (such as bumetanide) is only given
once phenobarbital has failed to stop seizures. Staley and co-
workers have advocated the use of bumetanide and phenobarbital
as the former augmented the efficacy of the latter (Dzhala et al.,
2005, 2008; Wong et al., 2013). However, these observations
are significantly hampered by the lack of investigations of
the dynamic alterations of chloride regulation that occur with
recurrent seizures. Indeed, using a triple chamber with the
two interconnected intact hippocampi and their connecting
commissures in three different chambers, we have determined
the alterations of GABAergic polarity after a determined number
of seizures. The regulation of (Cl−)I levels was found to be
highly seizure history dependent. Bumetanide neither prevented
the formation by recurrent seizures of an epileptogenic mirror
focus nor efficiently reduced their generation (Nardou et al.,
2009, 2011; Milenkovic´ and Rübsamen, 2011). Recurrent seizures
transformed the actions of GABA from inhibition to excitation
and phenobarbital blocked initial seizures but aggravated late
ones by reinforcing the excitatory actions of GABA (Figure 1;
Abbas andWhitfield, 2009; Nardou et al., 2011). This preparation
is not readily transposed to human health hence the need of
clinical trials. The logistics of clinical trials in a neonatal intensive
care setting as well as the population size of the NEMO trial
precludes a detailed analysis of the history of seizures prior to
bumetanide administration. In addition, the impossibility to use
bumetanide as first intention to treat also strongly hampered
the conclusions of the trial. All these factors must be included
in any evaluation of antiepileptic actions of bumetanide and in
particular the need to use it very shortly after the inaugurating
seizures. Collectively they suggest that bumetanide might reduce
the severity of some seizures but neither apply to all types nor
prevent the long term effects of repeated seizures and as such be
inefficient as an antiepileptic agent. In contrast to the results of
the NEMO trial, clinical and experimental observations suggest
that bumetanide might constitute a therapeutic tool to attenuate
several seemingly different brain disorders.
AUTISM SPECTRUM DISORDERS (ASD)
In naive animals, there is an oxytocin mediated abrupt fall of
chloride restricted to the delivery period endowed with neuro-
protective actions on the new born brain (Tyzio et al., 2006;
Witte et al., 2014). This is abolished in an animal model of
ASD and in fragile X (Brummett, 1981; Tyzio et al., 2014)
and maternal administration of bumetanide restored in off
springs physiological (Cl−)I levels and attenuated electrical
and behavioral parameters (Eftekhari et al., 2014; Tyzio et al.,
2014). Neocortical neurons have elevated (Cl−)I levels and
excitatory GABA (He et al., 2014). Bumetanide attenuated
the severity of ASD in 5–11 years old children in a double
blind, randomized study (Lemonnier et al., 2012). Similar
observations were made in a pilot case report (Lemonnier et al.,
2013). In an open-label trial pilot study in adolescents with
ASD treatment with bumetanide was associated with improved
emotion recognition and activation of brain regions involved
in social and emotional perception in functional magnetic
resonance imaging and neuropsychological testing (Hadjikhani
et al., 2015). Bumetanide also ameliorated sensory perception
in children/adolescents with ASD (Hadjikhani et al., 2015) and
altered EEG features (Bruining et al., 2015). Interestingly, in
contrast to seizures, benzodiazepines in ASD appear not to
be a negative factor for the use of bumetanide; this suggests
that chloride-regulating mechanisms are not severely affected in
ASD. Behavioral scores of ASD are more efficiently attenuated
by a combined educative and bumetanide treatment than by
educative/placebo treatment (Du et al., 2015). Interestingly,
oxytocin spray that reduces communication deficits (Guastella
et al., 2008) act like bumetanide by reducing (Cl−)I levels (Tyzio
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FIGURE 1 | (I) Phenobarbital (PB) attenuates early seizures but aggravates late ones. In a triple chamber with the 2 intact hippocampi interconnected by their
commissural connections in vitro, kainate was applied to one hippocampus generating interictal and ictal discharges in the ipsi-lateral hippocampus (dark trace) that
propagated to the contralateral hippocampus.PB application to the contralateral hippocampus (red trace) blocked the initial paroxysmal activity, (Ia) but aggravated
them when first applied after 15 recurrent ictal and interictal discharges (Ib). Right side: time frequency power plots to illustrate the different effects after a single and
any recurrent ictal and interictal discharges. Note the exclusively low frequency events recorded initially in the PB treated hippocampus and the enhanced high
frequency events observed after 15 paroxysmal activities. In (IIa–c), spikes evoked in the contralateral hippocampus by focal applications of GABA in the presence of
glutamate receptor antagonists. Intact hippocampus subjected to many recurrent IIds and IDs. PB (red) increased the number of spikes in comparison to control
(IIa-dark) and wash out (IIc-blue). (IIIa,b) Superimposed perforated-patch recordings of the currents evoked by GABA before (IIa-black), during (IIb-red), and after PB
wash out (IIc-blue) in the presence of antagonists of glutamate receptors. Note the enhanced GABA currents produced by PB (taken with permission from Nardou
et al., 2011).
et al., 2006). The effect of bumetanide on seizures that occur in
many children with ASD has not been determined as children
with epilepsies were not included in these trials.
SCHIZOPHRENIA
There is no suitable acceptable animal model of schizophrenia,
hence the difficulty in determining chloride equilibrium and
intracellular levels. But there is some indirect evidence that
chloride co-transporters might be affected. Thus, in human
and animal models, there is a reduction of the expression of
chloride co-transporters (Arion and Lewis, 2011; Hyde et al.,
2011; Kalkman, 2011). Also, drugs known to reduce (Cl−)I levels
notably oxytocin attenuate schizophrenia symptoms (Cacciotti-
Saija et al., 2015; Strauss et al., 2015). In a pilot case study,
we tested the effects of bumetanide in a patient suffering from
hallucinations and schizophrenia. We found a significant long
lasting reduction of the hallucinations; these recur when the
treatment was stopped (Lemonnier et al., 2016).
PARKINSON DISEASE
In 2 animal models of Parkinson Disease (PD), striatal
medium spiny neurons generated Giant GABAergic
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TABLE 1 | Effects of bumetanide on Parkinsonian motor symptoms in 4 patients.
Cases UPDRS III (OFF) UPDRS II (OFF) Patient’s main clinical effect Potassium Side effects
Baseline After 2 mo of
bumetanide
Baseline After 2 mo of
bumetanide
Baseline After 2 mo of
bumetanide
1 44 29 30 18 Improvement of parkinsonism 3.9 3.8 None
2 25 11 15 10 No change 4.1 4.2 Mild polyuria
3* 29 26 39 33 Improvement of gait 4.4 4.2 Mild polyuria
Fatigue
4 43 34 31 26 Improvement of balance 3.8 4.1 Moderate polyuria
They were treated for 2 months with the diuretic. Reproduced from (Damier et al., 2016).
*Patient 3 was assessed during subthalamic DBS ON. UPDRS indicates Unified Parkinson’s Disease Rating Scale; UPDRS III, motor scale in OFF-drug condition; UPDRS II, activities
of daily living in the worst conditions (OFF).
Currents that are readily blocked by L–Dopa and lesions
of the sub thalamic nucleus suggesting that they constitute
relevant signatures of PD (Dehorter et al., 2009, 2012). In
a pilot open trial, bumetanide improved gait and reduced
freezing in four patients with PD (Damier et al., 2016).
Interestingly, bumetanide seems to exert beneficial effects
on gait abnormalities and freezing of gait observed in two
of these patients (Table 1). These encouraging preliminary
observation need to be confirmed in further controlled
trials.
RETT SYNDROME
Rett syndrome includes autistic features and has been
often listed in ASD in several studies. Expression of the
Mecp2 mutation exclusively in GABAergic interneurons
generates several features of Rett syndrome stressing their
roles in Rett syndrome pathogenesis (Calfa et al., 2014).
In addition, the levels of KCC2 and NKCC1 in the CSF of
children with Rett syndrome are respectively reduced and
enhanced suggesting an alteration of chloride regulation
(Duarte et al., 2013). In human neurons transformed
from pluripotent cells of patients with Rett syndrome,
there is a deficit in KCC2 and a delay in the excitatory to
inhibitory GABA switch (Tang et al., 2016). Furthermore,
restoring KCC2 in mecp2 deficient mice rescued GABA
deficits.
PAIN
In a variety of experimental conditions, chloride co-transporters
are dys-regulated in motor spasticity, morphine-induced
hyperalgesia and chronic pain, and KCC2 activating agents
attenuate their severity (Boulenguez et al., 2010; Gagnon et al.,
2013). Oxytocin like bumetanide attenuated pain in pups
by reducing (Cl−)I levels in pain pathways (Mazzuca et al.,
2011).
In several instances, encouraging preclinical data fail in
clinical trials and the reasons for these failures are not always
straightforward. They might also lead to the abandon of the
animal model although heterogeneity of the clinical data might
also be a factor. Yet, with bumetanide, the situation is of
particular interest as the convergence of animal and human data
is reinforced by a fundamental conceptual series of observations
stressing the impact of a wide range of insults on (Cl−)I levels
paving the way to a common therapeutic strategy to many
disorders. Therefore, neither the severe side effects of bumetanide
on the hearing system of newborn with hypoxic ischemic
encephalopathy (HIE) nor its lack of efficacy in the NEMO study
bear relevance to many other disorders. High (Cl−)I levels and
excitatory GABA play a fundamental role in the pathogenesis of
many disorders, generating aberrant activities that perturb the
operation of behaviorally relevant oscillations. Bumetanide and
other drugs acting on chloride co-transporters can restore low
(Cl−)I levels in these disorders but may be contraindicated in
newborns because chloride co-transporters are still operative.
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